 |  |  |  |  |  |  |  |  |  |
SEARCH:
Sponsored by:
|
Lymphoma, Myeloma & Plasma Cell
|
|
|
Brentuximab vedotin was recently granted accelerated approval by the Food and Drug Administration for two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplantation (ASCT) or after failure of at least two multiagent chemotherapy regimens in... »
Commentaries
Brentuximab vedotin in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma
Brentuximab vedotin was recently granted accelerated approval by the Food and Drug Administration for two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplantation... »
Brentuximab vedotin was recently granted accelerated approval by the Food and Drug Administration for two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplantation... »
Community Translations
Brentuximab vedotin ushers in a new era in treating lymphomas
Hodgkin lymphoma represents one of the major successes of modern oncology. Several decades ago, it was fatal in most patients. With the development of the combination therapy mechlorethamine, vincristine, prednisone, and... »
Pomalidomide in lenalidomide-refractory multiple myeloma and carfilzomib in refractory and newly diagnosed multiple myeloma
What's new, what's important Treatment of multiple myeloma is evolving rapidly. It is tough to keep up with the rapid pace of new drugs, updates, and changes in the standard of care. In this issue of Community Oncology we... »
Hodgkin lymphoma represents one of the major successes of modern oncology. Several decades ago, it was fatal in most patients. With the development of the combination therapy mechlorethamine, vincristine, prednisone, and... »
Pomalidomide in lenalidomide-refractory multiple myeloma and carfilzomib in refractory and newly diagnosed multiple myeloma
What's new, what's important Treatment of multiple myeloma is evolving rapidly. It is tough to keep up with the rapid pace of new drugs, updates, and changes in the standard of care. In this issue of Community Oncology we... »
Current Issue
Community Oncology
Concentrates on original research,
rare cancers, quality of care in
community oncology, and practice guidelines. »
Latest Supplement
Highlights of the 6th Annual Community Oncology Conference. »
For past issues, click here »
calendar
More Calendar »